Transenterix Inc (TRXC) Coverage Initiated by Analysts at B. Riley
B. Riley initiated coverage on shares of Transenterix Inc (NYSEMKT:TRXC) in a research report released on Friday, StockTargetPrices.com reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.
Shares of Transenterix (NYSEMKT:TRXC) traded up 1.63% during trading on Friday, reaching $1.87. 471,944 shares of the company traded hands. Transenterix has a 12-month low of $1.03 and a 12-month high of $6.10. The firm’s 50-day moving average is $1.52 and its 200-day moving average is $2.03. The stock’s market capitalization is $215.05 million.
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC purchased a new position in shares of Transenterix during the first quarter valued at approximately $133,000. National Planning Corp purchased a new position in shares of Transenterix during the first quarter valued at approximately $365,000. Geode Capital Management LLC boosted its position in shares of Transenterix by 22.8% in the first quarter. Geode Capital Management LLC now owns 387,182 shares of the company’s stock valued at $1,645,000 after buying an additional 71,972 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Transenterix by 65.7% in the first quarter. State Street Corp now owns 684,234 shares of the company’s stock valued at $2,909,000 after buying an additional 271,278 shares in the last quarter.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.